Anti-hypertensive Drugs 乐鱼体育官网 Size
| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 4.50% |
| Fastest Growing 乐鱼体育官网 | Asia-Pacific |
| Largest 乐鱼体育官网 | North America |
| 乐鱼体育官网 Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Anti-hypertensive Drugs 乐鱼体育官网 Analysis
The Global Anti-hypertensive Drugs 乐鱼体育官网 is expected to register a CAGR of 4.5% during the forecast period.
The COVID-19 outbreak had a significant impact on people with hypertension. Also, due to lockdown and other restrictions imposed by governements to curb the spread of the infection from the Covid-19 virus, the lifestyle of patients with hypertension was severely impacted. As per the study titled "COVID-19 in Patients with Hypertension" published in Advances in Experimental Medicine and Biology in July 2021, hypertension individuals who have COVID-19 have an increased risk of mortality that is at least two times higher; nevertheless, renin-angiotensin-aldosterone system (RAAS) inhibitors that have been offer protection for this subgroup of patients which in turn expected to boost the growth of the anti-hypertensive drugs 乐鱼体育官网.
One of the leading factors responsible for the growth of the anti-hypertensive drugs 乐鱼体育官网 is the rising prevalence of hypertension among people around the world. The major known causes of hypertension are kidney diseases, diabetes, obstructive sleep apnea, and other cardiovascular diseases due to which the prevalence of hypertension has been observed a significant rise over the past few years. Also, some drugs can induce hypertension in patients with other diseases or disorders which in turn is expected to promote the growth of the studied 乐鱼体育官网. As per the updated May 2021 data from the World Health Organization, about 1.13 billion people around the world have hypertension, of which two-third are living in low- and middle-income countries. In the report published in June 2020 titled 'A Global View on Prevalence of Hypertension and Human Development Index' to determine the relationship between the prevalence of hypertension and human development index (HDI) concluded that the prevalence of hypertension ranged from 35% to 41% among 182 countries around the world. Thus, the rising prevalence of hypertension is expected to drive the growth of the anti-hypertensive drugs 乐鱼体育官网.
Certain other factors that will boost the growth of the anti-hypertensive drugs 乐鱼体育官网 include growing initiatives by private and government organizations and rising awareness about hypertension around the around. For instance, in May 2022, Glenmark Pharmaceuticals conclude the hypertension awareness symbol backed by the Association of Physicians of India (API) and Hypertension Society of India (HIS). Additionally, in May 2022, Namya Smile Foundation (NSF) organized an awareness campaign in India related to hypertension among people. The organization conducted a camp and checked the blood pressure and made them aware of various aspects of high blood pressure.
Whereas factors such as expiration of patent of multiple major drugs along with side effects associated with the hypertension treatment and rise in the availability of other non-pharmacological based therapy will restrict the growth of the anti-hypertensive drugs 乐鱼体育官网. For Instance, In December 2021, AbbVie, the parent company of Allergan, lost the patent of its anti-hypertensive drug, Bystolic (Nebivolol). Nebivolol is a beta blocker used to treat high blood pressure and heart failure. Additionally, 乐鱼体育官网 participants frequently introduce new products and use a variety of growth tactics in their particular segments, which is likely to spur 乐鱼体育官网 expansion. For Instance, in December 2021, Dr Reddy's Laboratories has launched Valsartan tablets, used for treatment of high blood pressure and heart failure, in the United States 乐鱼体育官网. The Valsartan tablet is the generic therapeutic equivalent of Diovan, approved by the United States Food and Drug Administration (USFDA). Similarly, in November 2021, Otsuka Pharmaceutical Co., Ltd. reported that Novartis Pharma K.K. (Novartis Pharma) has obtained approval in Japan for ENTREST 100 mg and 200 mg Tablets (generic name: sacubitril valsartan sodium hydrate) for the new indication of hypertension. This approval is Japan's first of an ARNI for the indication of hypertension.
Thus, all aforementioned factors expected to boost the 乐鱼体育官网 growth over the forecast period, However, multiple major drug patent expiration expected to hamper the 乐鱼体育官网 growth.
Anti-hypertensive Drugs 乐鱼体育官网 Trends
Diuretics Therapeutics Class is Expected to Hold a Significant 乐鱼体育官网 Share in the Forecast Period
Diuretics help in reducing the sodium and water from the body by inducing kidneys to release more sodium into the urine which leads to lower blood pressure as fluid flowing through the body is decreases. Diuretics are the preferred class of therapeutic drugs for the treatment of hypertension over others mainly because of their high efficacy, low cost, and low side effects as compared to other available therapeutic classes in the anti-hypertensive drugs 乐鱼体育官网.
Diuretics are of three types - thiazide diuretics, loop diuretics, and potassium-sparing diuretics, from which thiazide diuretics are the cornerstone of treatment for hypertension in most patients around the world. For instance, as per the research article published in July 2022, titled 'Loop Diuretics', Loop diuretics have received FDA approval to be used alone or in combination with other anti-hypertensives to treat hypertension. However, first-line therapy does not consist solely of loop diuretics. Loop diuretics can be used to address fluid overload conditions and alternative hypertension therapy. Moreover, according to the study titled "Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: protocol for a systematic review and network meta-analysis" published in the BMC Open Journal in February 2022, Thiazides have a proven track record of lowering blood pressure, have a good safety record, and are inexpensive. This makes them a popular choice for pharmaceutical treatment. Hydrochlorothiazide has less antihypertensive effectiveness than chlorthalidone and indapamide. Thus,m due to above benefits of the diuretics in the management of hypertension is anticipated to boost the segmrent growth over the forecast period.
Therefore, owing to the above-mentioned factors, the diuretics therapeutics class is expected to have highest growth as compared to others with the rise in the prevalence of hypertension cases around the world.
North America is Expected to Dominate the Anti-hypertensive Drugs 乐鱼体育官网 Over the Forecast Period
North America holds a major share in the anti-hypertensive drugs 乐鱼体育官网 and is expected to show a similar trend over the forecast period mainly due to the high prevalence of hypertension and diseases causing hypertension in the region. Additionally, the demand for prompt and accurate diagnosis and treatment of hypertension, identifying people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the prognosis of the disease are some of the key 乐鱼体育官网 drivers of the North American anti-hypertension 乐鱼体育官网.
In North America, the United States will hold the largest 乐鱼体育官网 in anti-hypertensive drugs 乐鱼体育官网 in the region. In the United States, the rising prevalence of hypertension is the major reason for the growth of the anti-hypertensive drug 乐鱼体育官网. As per the Center for Diseases Control and Prevention In July 2022, over half of adults (47 percent, or 116 million) have hypertension. Thus, the growing burden of hypertension in the United States is expected to rise in the demand anti-hypertensive drug thereby boost the 乐鱼体育官网 growth.
The other factors such as increasing awareness among the people about hypertension in the region. For instance, in November 2021, New public service announcements (PSAs) were released by the American Heart Association (AHA), American Medical Association (AMA), HHS Office of Minority Health (OMH), Health Resources & Services Administration (HRSA), and the Ad Council to encourage people to take charge of their health by self-monitoring their blood pressure and talking with a healthcare provider about their numbers.
Additionally, various strategies adopted by the key 乐鱼体育官网 players such as product launches and merger and acquisistion supports the 乐鱼体育官网 growth. In April 2021, United Therapeutics Corporation announced that the United States Food and Drug Administration approved its drug for the treatment of pulmonary hypertension associated with interstitial lung disease, known as Tyvaso (Treprostinil).
Thus, the North America is expected to hold major 乐鱼体育官网 share in the anti-hypertensive 乐鱼体育官网.
Anti-hypertensive Drugs Industry Overview
The anti-hypertensive drugs 乐鱼体育官网 is highly competitive due to the presence of a number of pharmaceutical companies. Companies such as AstraZeneca PLC, C.H. Boehringer Sohn AG & Ko. KG, Daiichi Sankyo Company Limited, Johnson & Johnson Ltd, Lupin Limited, Merck KGaA ., Novartis AG, among others, hold a substantial 乐鱼体育官网 share in the anti-hypertensive drugs 乐鱼体育官网.
Anti-hypertensive Drugs 乐鱼体育官网 Leaders
-
Pfizer Inc.
-
C.H. Boehringer Sohn AG & Ko. KG
-
Noden Pharma DAC
-
Daiichi Sankyo Company Limited
-
Merck KGaA
- *Disclaimer: Major Players sorted in no particular order
Anti-hypertensive Drugs 乐鱼体育官网 News
- In May 2022, Hanmi Pharmaceutical revealed that it will start 乐鱼体育官网ing its blockbuster hypertension drug Amosartan under the brand name Meiyaping in China. It marked the first homegrown blood pressure combination therapy to enter the Chinese 乐鱼体育官网.
- In March 2022, Pfizer Inc. has recall a blood pressure drug because of elevated levels of a potentially cancer-causing impurity.
Anti-hypertensive Drugs Industry Segmentation
As per the scope of the report, anti-hypertensive drugs are referred to as a class of drugs that are used in the treatment of hypertension (high blood pressure) disorder. There are many classes of anti-hypertensive drugs which can reduce blood pressure by different means, and thus, preventing the complications associated with high blood pressure, including stroke and myocardial infarction. The Anti-hypertensive Drugs 乐鱼体育官网 is segmented by therapeutic class (diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta blockers, alpha blockers, renin inhibitors, calcium channel blockers, and other therapeutic classes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The 乐鱼体育官网 report also covers the estimated 乐鱼体育官网 sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| Therapeutic Class | Diuretics | ||
| Angiotensin Converting Enzyme (ACE) Inhibitors | |||
| Angiotensin Receptor Blockers (ARBs) | |||
| Beta Blockers | |||
| Alpha Blockers | |||
| Renin Inhibitors | |||
| Calcium Channel Blockers | |||
| Other Therapeutic Classes | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Diuretics |
| Angiotensin Converting Enzyme (ACE) Inhibitors |
| Angiotensin Receptor Blockers (ARBs) |
| Beta Blockers |
| Alpha Blockers |
| Renin Inhibitors |
| Calcium Channel Blockers |
| Other Therapeutic Classes |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Anti-hypertensive Drugs 乐鱼体育官网 Research FAQs
What is the current Global Anti-hypertensive Drugs 乐鱼体育官网 size?
The Global Anti-hypertensive Drugs 乐鱼体育官网 is projected to register a CAGR of 4.5% during the forecast period (2025-2030)
Who are the key players in Global Anti-hypertensive Drugs 乐鱼体育官网?
Pfizer Inc., C.H. Boehringer Sohn AG & Ko. KG, Noden Pharma DAC, Daiichi Sankyo Company Limited and Merck KGaA are the major companies operating in the Global Anti-hypertensive Drugs 乐鱼体育官网.
Which is the fastest growing region in Global Anti-hypertensive Drugs 乐鱼体育官网?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Anti-hypertensive Drugs 乐鱼体育官网?
In 2025, the North America accounts for the largest 乐鱼体育官网 share in Global Anti-hypertensive Drugs 乐鱼体育官网.
What years does this Global Anti-hypertensive Drugs 乐鱼体育官网 cover?
The report covers the Global Anti-hypertensive Drugs 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Anti-hypertensive Drugs 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Antihypertensive Drugs Industry Report
The global antihypertensive drugs 乐鱼体育官网 is poised for substantial growth, driven by increasing hypertension prevalence and a focus on early diagnosis and effective treatment. Key 乐鱼体育官网 segments such as diuretics, ACE inhibitors, calcium channel blockers, vasodilators, and beta-blockers are crucial, each offering unique therapeutic benefits tailored to patient needs. North America currently leads due to high drug adoption rates and advanced healthcare infrastructure, while Asia-Pacific is expected to see rapid growth due to rising health awareness and an aging population. The 乐鱼体育官网 expansion is further fueled by innovative drug formulations, combination therapies, and strategic R&D collaborations aimed at developing safer, more effective treatments. For detailed 乐鱼体育官网 insights and a forecast outlook, access a free report PDF sample from Mordor Intelligence鈩� Industry Reports.
